Treatment patterns and resource utilization among elderly Medicare patients with HR+/HER2-metastatic breast cancer

被引：0
|
作者：
Goyal, R. K.
Carter, G. C.
Nagar, S. N.
Smyth, E. N.
Price, G. L.
Huang, Y-J
Bromund, J. L.
Li, L.
Schilder, J. M.
Davis, K. L.
Kaye, J. A.
机构：
[1] RTI Hlth Solut, Res Triangle Pk, NC USA
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
[3] RTI Hlth Solut, Waltham, MA USA
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-08-19
引用
收藏
页数：2
相关论文
共 50 条
  • [31] FDA Approves Sacituzumab Govitecan for Pretreated HR+/HER2-Metastatic Breast Cancer
    不详
    AMERICAN JOURNAL OF MANAGED CARE, 2023, 29 (04): : SP315 - SP315
  • [32] Treatment patterns and characteristics of post-menopausal women with HR+/HER2-metastatic breast cancer receiving everolimus.
    Vekeman, Francis
    Hao, Yanni
    Cheng, Wendy Y.
    Fortier, Jonathan
    Robitaille, Marie-Noelle
    Duh, Mei Sheng
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [33] Dosing patterns and economic burden of drug wastage among postmenopausal women with HR+/HER2-metastatic breast cancer receiving palbociclib
    Dalal, Anand A.
    Gagnon-Sanschagrin, Patrick
    Burne, Rebecca
    Guerin, Annie
    Gauthier, Genevieve
    Small, Tania
    Niravath, Polly
    CANCER RESEARCH, 2018, 78 (04)
  • [34] Treatment Patterns and Health Resource Utilization in Patients With HR+/ HER2- Locally Advanced or Metastatic Breast Cancer in Real-World Setting in Taiwan
    Novick, Diego
    Rajan, Narayan
    Wei, Alice
    Cheng, Rebecca
    Colman, Sam
    Szende, Agota
    VALUE IN HEALTH REGIONAL ISSUES, 2023, 36 : 98 - 104
  • [35] Real world evidence study on treatment patterns and health resource utilization in patients with HR+/HER2- locally advanced or metastatic breast cancer in Korea
    Novick, Diego
    Lee, Sae Young
    Koo, Dong Hyun
    Szende, Agota
    Colman, Sam
    JOURNAL OF DRUG ASSESSMENT, 2022, 11 (01) : 12 - 19
  • [36] TREATMENT PATTERNS FOLLOWING FIRST LINE CDK4/6 INHIBITOR PROGRESSION IN HR+, HER2-METASTATIC BREAST CANCER
    Behan, E.
    Bansal, A.
    Veenstra, D.
    VALUE IN HEALTH, 2024, 27 (06) : S406 - S406
  • [37] A multicenter analysis of treatment patterns and clinical outcomes of subsequent therapies after progression on palbociclib in HR+/HER2-metastatic breast cancer
    Li, Yi
    Li, Wei
    Gong, Chengcheng
    Zheng, Yabin
    Ouyang, Quchang
    Xie, Ning
    Qu, Qing
    Ge, Rui
    Wang, Biyun
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [38] Treatment patterns for young women with HR+/HER2-metastatic breast cancer in the United States in the era of CDK 4/6 inhibitors
    Burstein, Harold J.
    Mayer, Erica L.
    DeMichele, Angela
    Harnett, James
    Mardekian, Jack
    McRoy, Lynn
    Bartlett, Cynthia Huang
    Koehler, Maria
    Rimawi, Mothaffar Fahed
    CANCER RESEARCH, 2018, 78 (04)
  • [39] Physician experiences and preferences in the treatment of HR+/HER2-metastatic breast cancer in the United States: aphysician survey
    Lin, Peggy L.
    Hao, Yanni
    Xie, Jipan
    Li, Nanxin
    Zhong, Yichen
    Zhou, Zhou
    Signorovitch, James E.
    Wu, Eric Q.
    CANCER MEDICINE, 2016, 5 (02): : 209 - 220
  • [40] Patient Preferences for HR+/HER2-Metastatic Breast Cancer Treatments in Italy: A Qualitative Assessment
    Arpino, Grazia
    De Angelis, Carmine
    Gerratana, Lorenzo
    Lambertini, Matteo
    Igidbashian, Sarah
    Bellini, Martina
    Giuntoli, Serena
    Guillaume, Xavier
    Behillil, Julie
    Graziani-Taugeron, Claire
    CANCER RESEARCH, 2024, 84 (09)
12345